Actively Recruiting
Study of BGT007 Cell Therapy for Adults With Recurrent or Metastatic Refractory Digestive System Cancers
Led by The Affiliated Hospital of Xuzhou Medical University · Updated on 2023-10-27
14
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and initial effectiveness of BGT007 cell therapy in patients with recurrent, metastatic, or refractory digestive system tumors, including esophageal, gastric, pancreatic, or colorectal cancers. This early-phase exploratory trial aims to determine the best dose of BGT007 cells for safe and effective treatment by gradually increasing doses and monitoring patients closely. The study is conducted as a single-arm, open-label trial using an improved 33 dose escalation design. Participants receive a single intravenous infusion of BGT007 cells at one of five dose levels, ranging from 5.0 107 to 3.0 109 cells. The first two dose groups include one subject each, while the remaining three groups follow the traditional 33 dose escalation method. After the infusion on day 0, patients are observed for at least four weeks to monitor dose-limiting toxicities and safety. Dose escalation proceeds based on these observations. During the study, participants undergo regular assessments to monitor safety and treatment effects, including measuring dose-limiting toxicities from day 0 to day 28. Additional outcomes tracked over 12 months include maximum concentration C max, time to reach maximum concentration T max, objective response rate ORR, and progression-free survival PFS. The study duration and follow-up vary per participant, focusing on careful monitoring of safety and initial efficacy.
CONDITIONS
Brief Title
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here